April 25, 2025 - 07:17

A special themed section of research papers has been published, shedding light on the intricate health economics surrounding Alzheimer's disease and related dementias (ADRD). This collection aims to provide essential insights as the aging population continues to expand and new treatments are developed. The research highlights the multifaceted economic challenges posed by ADRD, including the financial burden on healthcare systems and the impact on patients and caregivers.
As the prevalence of dementia rises, understanding the economic implications becomes increasingly critical for policymakers and healthcare providers. The findings emphasize the need for a comprehensive approach to address the long-term care costs, the value of innovative therapies, and the importance of investing in preventive measures. This body of work not only serves as a valuable resource for future research but also aims to guide effective policy decisions in managing ADRD, ultimately improving outcomes for patients and society as a whole.
May 9, 2026 - 22:43
College of Pharmacy & Health Sciences confers 206 degrees - NewsThe Campbell University College of Pharmacy & Health Sciences held its spring commencement ceremony to honor the achievements of the Class of 2026. A total of 206 degrees were conferred during the...
May 9, 2026 - 02:40
California Becomes First State to Offer Free Diapers for Every NewbornCalifornia is set to launch a first-of-its-kind program that will provide free diapers to every newborn in the state. The initiative, which makes California the first state in the country to offer...
May 8, 2026 - 11:45
Maryland ranked high among states for public health preparedness, but could be doing moreMaryland continues to rank among the top states in the nation for its ability to handle public health emergencies, according to a recent analysis by a national health policy organization. The state...
May 7, 2026 - 18:47
Healthy Returns: First Ozempic generics in Canada will be a test case for Novo NordiskThe arrival of the first generic versions of semaglutide in Canada is being watched closely as a potential turning point for Novo Nordisk`s dominance in the global weight-loss and diabetes market....